Invitae Corporation (NVTA): Price and Financial Metrics


Invitae Corporation (NVTA)

Today's Latest Price: $44.30 USD

0.96 (-2.12%)

Updated Oct 26 8:59am

Add NVTA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

NVTA Stock Summary

  • With a price/sales ratio of 24.88, Invitae Corp has a higher such ratio than 93.48% of stocks in our set.
  • With a year-over-year growth in debt of 154.33%, Invitae Corp's debt growth rate surpasses 90.57% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Invitae Corp is reporting a growth rate of 185.7%; that's higher than 93.17% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Invitae Corp, a group of peers worth examining would be GWRE, WORK, XBIT, MODN, and SOLO.
  • NVTA's SEC filings can be seen here. And to visit Invitae Corp's official web site, go to www.invitae.com.

NVTA Stock Price Chart Interactive Chart >

Price chart for NVTA

NVTA Price/Volume Stats

Current price $44.30 52-week high $55.38
Prev. close $45.26 52-week low $7.41
Day low $44.30 Volume 1,568
Day high $44.30 Avg. volume 3,060,354
50-day MA $40.66 Dividend yield N/A
200-day MA $25.80 Market Cap 5.84B

Invitae Corporation (NVTA) Company Bio


Invitae Corporation is a company that utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for physicians and their patients. The company was founded in 2012 and is based in San Francisco, California.


NVTA Latest News Stream


Event/Time News Detail
Loading, please wait...

NVTA Latest Social Stream


Loading social stream, please wait...

View Full NVTA Social Stream

Latest NVTA News From Around the Web

Below are the latest news stories about Invitae Corp that investors may wish to consider to help them evaluate NVTA as an investment opportunity.

The Daily Biotech Pulse: FDA Nod For Pfizer, Sorrento's COVID-19 Antibody Animal Data, Orphazyme's Wall Street Debut

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 28) 10X Genomics Inc (NASDAQ: TXG ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Beigene Ltd (NASDAQ: BGNE ) Cardiff Oncology Inc (NASDAQ: CRDF ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Evogene Ltd (NASDAQ: EVGN ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) InVitae Corp (NYSE: NVTA ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kura Oncology Inc (NASDAQ: KURA ) Lantern Pharma Inc. (NASDAQ: LTRN ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Prelude Therapeutics Incorporated (NASDAQ: PRLD ) (listed Thursday) Seattle Genetics, Inc. (NASDAQ: SGEN ) Shockwave Medical Inc...

Benzinga | September 29, 2020

The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) ...

Benzinga | September 17, 2020

The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than...

Benzinga | September 16, 2020

Invitae Appoints Kimber Lockhart to its Board of Directors

SAN FRANCISCO, Sept. 11, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the appointment of Kimber Lockhart to its Board of Directors, effective September 10, 2020. "We are excited to welcome Kimber Lockhart to our board of…

PR Newswire | September 11, 2020

[FREE SLIDE DECK] Key Players in Genetic Testing

Summary List Placement The human genome was sequenced – or read in its entirety – for the first time in 2003, after more than 20 years of work. In the ensuing decades, genetic information catapulted into mainstream healthcare driven largely by the rapid decline in cost for DNA sequencing technology. Today, there is a massive opportunity for genetic testing firms to help healthcare organizations use DNA to steer more personalized treatments. In the Key Players in Genetic Testing report, Insider Intelligence gives an overview of the four genetic testing companies – 23andMe, Ancestry, Color, and Invitae – that are racing to the forefront of healthcare. This exclusive report can be yours for FREE today. Join the conversation about this story »

Business Insider | September 9, 2020

Read More 'NVTA' Stories Here

NVTA Price Returns

1-mo -0.83%
3-mo 49.71%
6-mo 153.29%
1-year 163.22%
3-year 471.61%
5-year 170.95%
YTD 174.64%
2019 45.84%
2018 21.81%
2017 242.64%
2016 -75.80%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7152 seconds.